Volume 7, Issue 3 (2021)                   Pharm Biomed Res 2021, 7(3): 0-0 | Back to browse issues page

XML Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Sharifi N, Kohpeima Jahromi V, Rahmanian M, Raoofi R, Zahedi R. Enhancing the Rational Use of Albumin and Intravenous Pantoprazole by implementing pharmaceutical guidelines in Hospitals. Pharm Biomed Res. 2021; 7 (3)
URL: http://pbr.mazums.ac.ir/article-1-386-en.html
1- Department of Public Health, Jahrom University of Medical Sciences, Jahrom, Iran.
2- Department of Anesthesiology, Jahrom University of Medical Sciences, Jahrom, Iran
3- Department of Infectious Diseases, Jahrom University of Medical Sciences, Jahrom, Iran
4- Research Center for Social Determinants of Health, Jahrom University of Medical Sciences, Jahrom, Iran
Abstract:   (149 Views)
Background: Irrational use of drugs is a serious problem throughout the world, especially in developing countries. Scientific evidence has announced albumin and intravenous pantoprazole are two expensive drugs that are being relatively utilized irrationally in hospitals without the use of the guidelines.
Objectives: Looking at health cost management policy in Iran, this study aims to evaluate the effect of implementing pharmaceutical guidelines to rationalize and reduce the use of albumin and intravenous pantoprazole and the related inappropriate cost.
Methods: This quasi-experimental study was conducted during a 3-year period, from January 2016 to October 2018 in two teaching hospitals in jahrom. Pharmaceutical guidelines were implemented throughout the physician training and a pharmacist-led intervention and supervising. All inpatient prescriptions of the two studied medicines were evaluated.
Results: Before the intervention (June 2016), an average of 357 albumin vials were used monthly and after the interventions, 166 and 167 vials were used in 2017 and 2018, respectively. The reduction of albumin use was 48% which was significant (P = 0.002). Annual cost-saving was estimated to be 25,000 USD. In comparison to the previous year, there was 46% and 70% reduction in the mean number of pantoprazole vials prescribed in 2017 and 2018, respectively (P = 0.005).
Consumption of pantoprazole was 1457 vials per month in 2017 and 795 in 2018 which was significant (P = 0.002). Cost-saving in intravenous pantoprazole was estimated to be 16,000 USD in 2017 and 25,000 USD in 2018.
Conclusion: Prescription strategies such as pharmaceutical guidelines with educational measures, pharmacist-led intervention, monitoring the prescribing drug, and feedback to prescribers can significantly decrease the inappropriate use of expensive drugs and their costs.

     
Type of Study: Original Research | Subject: Rational Drug Prescribing

Add your comments about this article : Your username or Email:
CAPTCHA

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2021 CC BY-NC 4.0 | Pharmaceutical and Biomedical Research

Designed & Developed by : Yektaweb